ASCO Genitourinary Cancers Symposium

 

Videos
08:55

ASCO Genitourinary Cancers Symposium

ASCO GU 2022: Community Oncologists’ Perceptions of and Barriers to Access for 177Lu-PSMA-617 in mCRPC

FEATURING Ajeet Gajra
  • 68 views
  • March 30, 2022
09:36

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment With Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible MIBC

FEATURING Nataliya Mar
  • 176 views
  • March 23, 2022
  • 1
08:54

ASCO Genitourinary Cancers Symposium

Trials in Progress in Neoadjuvant Systemic Therapy in MIBC

FEATURING Petros Grivas
  • 188 views
  • March 16, 2022
11:23

ASCO Genitourinary Cancers Symposium

ASCO GU 2022: An AI-Derived Digital Pathology-Based Biomarker to Predict the Benefit of ADT in Localized Prostate Cancer With Validation in NRG/RTOG 9408

FEATURING Daniel Spratt
  • 33 views
  • March 14, 2022
12:14

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up: Efficacy and Safety of Nivo+Ipi vs. Sunitinib for 1L Treatment of Advanced sRCC

FEATURING Scott Tykodi
  • 173 views
  • March 14, 2022
06:52

ASCO Genitourinary Cancers Symposium

ASCO GU 2022: Tumor Mutational Burden as a Predictive Biomarker for Immune CPI vs. Chemo Benefit in 1L mUC

FEATURING Shilpa Gupta
  • 61 views
  • March 14, 2022
20:27

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Radiation Therapy in Localized Prostate Cancer: Changing Horizons

FEATURING Alberto Bossi
  • 33 views
  • March 14, 2022
13:49

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Multi-Institutional Matched Comparison of Radical Cystectomy to Trimodality Therapy for MIBC

FEATURING Alexandre Zlotta
  • 117 views
  • March 14, 2022
09:54

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on the Randomized Meet-URO12 Trial: Niraparib + BSC vs. BSC Alone as Maintenance Treatment in Advanced UC Patients Whose Disease Did Not Progress After 1L Platinum-Based Chemotherapy

FEATURING Massimo Di Maio
  • 77 views
  • March 14, 2022
04:06

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on the Phase 3 TITAN Study: The Effect of Prior Docetaxel Treatment on Efficacy & Safety of Apalutamide + ADT in mCSPC

FEATURING Kim Chi
  • 146 views
  • March 14, 2022
  • 1
10:53

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 TROPHY-U-01 Cohort 3: Sacituzumab Govitecan + Pembrolizumab in mUC After Progression With Platinum-Based Regimens

FEATURING Petros Grivas
  • 98 views
  • March 8, 2022
  • 1
05:41

Fred Saad

ARASENS Trial Updates: OS With Darolutamide vs. Placebo in Combination With ADT & Docetaxel for mHSPC

  • 354 views
  • March 8, 2022
11:45

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 PROpel Phase III Trial Highlights: Olaparib & Abiraterone vs. Placebo & Abiraterone as 1L Therapy for mCRPC

FEATURING Fred Saad
  • 353 views
  • March 8, 2022
  • 2
08:02

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on the ARIES Trial: 1L Avelumab in PD-L1+ Metastatic or Locally Advanced Urothelial Cancer Patients Unfit for Cisplatin

FEATURING Roberto Iacovelli
  • 17 views
  • March 8, 2022
11:11

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on a Study EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment With Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible MIBC

FEATURING Daniel Petrylak
  • 150 views
  • March 8, 2022
07:47

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on a Phase II Study of Nivo + Ipi for Advanced GU Malignancies With Neuroendocrine Differentiation

FEATURING Bradley McGregor
  • 78 views
  • March 8, 2022
11:32

ASCO Genitourinary Cancers Symposium

ASCO GU 2022: Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive NMIBC

FEATURING Sam Chang
  • 16 views
  • March 8, 2022
10:01

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Management of Toxicities With Novel Systemic Therapies in Urothelial Carcinoma

FEATURING Thomas Flaig
  • 14 views
  • March 8, 2022
07:12

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Bone Mineral Density in De Novo mCSPC Treated With/Without Abiraterone + Prednisone: PEACE-1 Phase 3 Trial Updates

FEATURING Guilhem Roubaud
  • 77 views
  • March 2, 2022
08:35

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on 1L Axitinib + Pembro in Advanced RCC: Real-World Treatment Outcomes in the United States

FEATURING Yousef Zakharia
  • 97 views
  • March 2, 2022
04:01

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Nivo + Cabo vs. Sunitinib for Advanced RCC: Final OS Analysis and Organ-Specific Target Lesion Assessments w/ 2-Year Follow-Up in CheckMate 9ER

FEATURING Thomas Powles
  • 251 views
  • March 2, 2022
05:00

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 OS in mHSPC Treated With Enzalutamide + ADT by High/Low Disease Volume and Progression to (de Novo) mHSPC (M0/M1 at Diagnosis): Post Hoc Analysis of the Phase 3 ARCHES Trial

FEATURING Andrew Armstrong
  • 44 views
  • March 2, 2022
06:48

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 CABOSEQ Trial Updates on the Efficacy of Cabozantinib Post Up-Front Immuno-Oncology Combinations in Advanced RCC: Results From the International mRCC Database Consortium

FEATURING Vishal Navani
  • 38 views
  • March 1, 2022
08:33

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on the Immune Profiling of Advanced Prostate Cancer Harboring Homologous Recombination Deficiency

FEATURING Maryam Soleimani
  • 148 views
  • February 28, 2022
05:43

ASCO Genitourinary Cancers Symposium

ASCO GU 2022: A Phase I/II Study of Nivo & Axitinib in Patients With Advanced RCC

FEATURING Matthew Zibelman
  • 24 views
  • February 28, 2022
06:49

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Gem & Cis as Neoadjuvant Chemo in High-Grade UTUC: Final Results of a Multicenter Prospective Phase II Clinical Trial

FEATURING Wesley Yip
  • 85 views
  • February 28, 2022
16:00

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

FEATURING Michael Dean
  • 177 views
  • February 26, 2022
  • 1
07:40

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Futibatinib + Pembro in Advanced/Metastatic UC: Preliminary Safety Results From a Phase 2 Study

FEATURING Vadim Koshkin
  • 122 views
  • February 26, 2022
09:23

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in Patients With RCC: Abstract 287 Updates

FEATURING Rana McKay
  • 69 views
  • February 24, 2022
07:53

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on Neoadjuvant Cabozantinib in Locally Advanced Non-Metastatic ccRCC: Phase 2 Study

FEATURING Mehmet Bilen
  • 55 views
  • February 24, 2022
06:58

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on the Updated OS Analysis for Docetaxel +/- Capivasertib in mCRPC: A Phase II ProCAID Trial Updates

FEATURING Simon Crabb
  • 21 views
  • February 24, 2022
11:54

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Efficacy & Safety of Continuing Enza in Chemo-Naïve mCRPC Patients Treated With Docetaxel + Prednisolone Who Have Progressed on Enza: Phase 3b PRESIDE Study

FEATURING Axel Merseburger
  • 55 views
  • February 24, 2022
03:02

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Pembro as Post-Nephrectomy Adjuvant Therapy for RCC: Results From the 30-Month Follow-Up of the KEYNOTE-564

FEATURING Toni Choueiri
  • 112 views
  • February 24, 2022
07:45

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Cabozantinib in Advanced RCC After the Failure of CPI Therapy: Final Analysis of a Non-Interventional CaboCHECK Study

FEATURING Viktor Grünwald
  • 28 views
  • February 24, 2022
13:17

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on the ADCs in Advanced Urothelial Cancer: Clinical Perspective

FEATURING Scott Tagawa
  • 154 views
  • February 24, 2022
  • 2
05:16

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Survival Outcomes and Characterization of Patients With mCSPC Undergoing Intensified ADT Who Do Not Achieve an Optimal PSA Response

FEATURING Nicolas Sayegh
  • 180 views
  • February 24, 2022
16:34

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oligometastatic Renal Cell Carcinoma

FEATURING Naomi Haas
  • 134 views
  • February 24, 2022